Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

CE 224,535 is being developed for the treatment of rheumatoid arthritis. The purpose of this study is to evaluate the safety and tolerability of CE 224,535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Methotrexate

Criteria

Inclusion Criteria:

• Adults patients with rheumatoid arthritis

• Patients who have received stable weekly doses of oral methotrexate (5 to 25 mg/week administered as a single dose) for a minimum of 28 days (4 weeks/4 doses)

Exclusion Criteria:

• History of chronic infectious disease such as genitourinary, pulmonary or sinus infections.

• Any current or known malignancy or history of malignancy within the previous 5 years

• Pregnant or lactating women; women of child-bearing potential who are unwilling to unable to use an acceptable method of birth control during the study